CytRx Corp. (CYTR)

1.07
0.02 1.90
NASDAQ : Health Technology
Prev Close 1.05
Open 1.04
Day Low/High 1.04 / 1.07
52 Wk Low/High 1.00 / 2.95
Volume 51.26K
Avg Volume 115.80K
Exchange NASDAQ
Shares Outstanding 33.64M
Market Cap 36.33M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CytRx Corporation To Present At The H.C. Wainwright & Co. 20th Annual Global Investment Conference In New York City September 4-6, 2018

CytRx Corporation To Present At The H.C. Wainwright & Co. 20th Annual Global Investment Conference In New York City September 4-6, 2018

LOS ANGELES, Aug. 27, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr.

CytRx Corporation Reports Second Quarter 2018 Financial Results

CytRx Corporation Reports Second Quarter 2018 Financial Results

Substantial Reduction in CytRx Cash Burn Rate This Quarter

CytRx Corporation Pays Off Balance Of Outstanding Debt

CytRx Corporation Pays Off Balance Of Outstanding Debt

LOS ANGELES, Aug. 1, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has made the final scheduled payment under a long-term loan facility...

CytRx Corporation To Hold Second Quarter 2018 Financial Results Conference Call And Webcast On Monday, August 6, 2018

CytRx Corporation To Hold Second Quarter 2018 Financial Results Conference Call And Webcast On Monday, August 6, 2018

LOS ANGELES, July 30, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial results for the quarter ended June 30, 2018 on...

CytRx Announces Centurion BioPharma Corporation's Filing Of A Provisional Patent Application

CytRx Announces Centurion BioPharma Corporation's Filing Of A Provisional Patent Application

Breakthrough Personalized Medicine Companion Diagnostic Filed for its Albumin-binding Drug Candidates

CytRx Corporation Announces Expiration Of Outstanding Warrants

CytRx Corporation Announces Expiration Of Outstanding Warrants

Warrants for 3.2 Million Common Shares Expired July 20, 2018

CytRx Corporation To Present At The Singular Research Summer Solstice 2018 Conference

CytRx Corporation To Present At The Singular Research Summer Solstice 2018 Conference

LOS ANGELES, July 16, 2018 /PRNewswire/ --  CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr.

CytRx Corporation Highlights Aldoxorubicin Included In New NantCell Inc. Triple Negative Breast Cancer Clinical Trial

CytRx Corporation Highlights Aldoxorubicin Included In New NantCell Inc. Triple Negative Breast Cancer Clinical Trial

This New Trial Represents the Third NantCell Study Evaluating Aldoxorubicin Combined with Immunotherapy or Cell-Based Therapy

CytRx Corporation Joins Russell Microcap® Index

CytRx Corporation Joins Russell Microcap® Index

LOS ANGELES, June 25, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has been added to the Russell Microcap ® Index, effective upon the market...

CytRx Corporation Highlights Review Of NantCell Inc's Aldoxorubicin Published In Future Oncology

CytRx Corporation Highlights Review Of NantCell Inc's Aldoxorubicin Published In Future Oncology

Clinical studies with aldoxorubicin demonstrated increased progression-free survival and tumor response with low cardiotoxicity

CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented At The American Society Of Clinical Oncology 2018 Annual Meeting

CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented At The American Society Of Clinical Oncology 2018 Annual Meeting

Data Show Aldoxorubicin, Alone or in Combination with Ifosfamide, Lacks Cardiotoxicity with Doxorubicin Equivalent Doses Beyond 1000 mg/m2

CytRx Corporation Launches Centurion BioPharma Corporation To Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates

CytRx Corporation Launches Centurion BioPharma Corporation To Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates

LOS ANGELES, June 4, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the formation and launch of Centurion BioPharma Corporation, a private wholly owned...

CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data To Be Presented At The American Society Of Clinical Oncology 2018 Annual Meeting

Data Show Aldoxorubicin, Alone or in Combination with Ifosfamide, Lacks Cardiotoxicity with Doxorubicin Equivalent Doses Beyond 1000 mg/m²

CytRx Corporation To Present At OneMed NYC Oncology Investor Conference 2018

New President and Chief Operating Officer Mr. Eric Curtis will be Representing CytRx Corporation

CytRx Corporation Names Eric L. Curtis As Its President And Chief Operating Officer

Seasoned Professional with 25 Years of Experience in Both Oncology and Orphan Diseases, Including Development and Commercialization of Approved Drugs Votrient®, Doxil®, Velcade® and Benlysta®

Interesting CYTR Call Options For March 2018

Interesting CYTR Call Options For March 2018

Investors in CytRx Corp saw new options begin trading today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Goodbye CytRx, Your Game Is Over

Goodbye CytRx, Your Game Is Over

Hope springs eternal, until it's dashed on the rocks and buried at sea.

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

First Week of CYTR September 15th Options Trading

First Week of CYTR September 15th Options Trading

Investors in CytRx Corp saw new options begin trading this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx announced a plan Tuesday to seek U.S. marketing approval of aldoxorubicin based more on hocus-pocus than credible study results.

TheStreet Quant Rating: D- (Sell)